shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Notice of Intent to Publish a Funding Opportunity Announcement for Facilitating Preclinical and Early Phase Human Studies for New Therapeutics (UG3/UH3 Clinical Trial Optional)

    NOT-AG-24-025

    Opening date 27 Jun 2024, 12:00AM

    Closing date N/A

    Funding Opportunity Number: NOT-AG-24-025

    Opportunity Category: Discretionary

    CFDA Number(s): 93.866 -- Aging Research

    Cost Sharing or Matching Requirement: No

    Posted Date: Jun 27, 2024 12:00:00 AM EDT

    Closing Date: N/A

    Estimated Total Program Funding: 2500000

    Eligible Applicants: Public and State controlled institutions of higher education,Small businesses,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Independent school districts,Native American tribal governments (Federally recognized),Public housing authorities/Indian housing authorities,For profit organizations other than small businesses,State governments,County governments,Private institutions of higher education,Others (see text field entitled "Additional Information on Eligibility" for clarification)

    Description: This Notice informs that the National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) inviting applications on T1 translational aging research (i.e., bench to bedside) which focus on advancing new therapeutics from preclinical stages to first-in-human (FIH) trials for aging-related conditions such as sarcopenia, physical functional impairments, heart failure with preserved ejection fraction (HFpEF), and deficits such as immunosenescence.� Biologics or stem/progenitor cell therapies for improving injury repair in older adults (e.g., fractures, wound healing) may be proposed. This may include treatments with cytokines, trophic factors, etc., to improve stem/progenitor cell function to promote more efficient repair of injuries or wounds, as well as homeostasis of the damaged tissues. �Proposed projects should clearly state the relationship between candidate compound or therapeutic target of interest for preclinical development to the clinical indication (i.e., aging-related condition of interest). Applications focusing on neurodegenerative diseases and Alzheimer�s disease and Alzheimer�s disease related dementias (AD/ADRD) will be outside the scope of the NOFO. The NOFO is expected to utilize the Exploratory/Developmental Phased Award Cooperative Agreement UG3/UH3 activity code, which is a milestone-driven, phased innovation mechanism. The UG3/UH3 application must be submitted as a single application. Investigators must propose annual milestones with timelines for the UG3 and UH3 phases. The specified milestones should be quantifiable goals (or deliverables) which can be used to monitor progress at each phase, and for go/no-go decision-making at the UG3/UH3 transition point. This notice is provided to enable advance planning by potential applicants to identify potential collaborators, coordinate and obtain approvals (if needed) for required research resources, and prepare a well-developed research plan for advancing a therapeutic through the stages of preclinical drug development and early phase human studies. The NOFO is expected to be published summer 2024 with an anticipated application due date in fall 2024.�These are estimated time frames, and they may change.

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept